ASGR2抗体;ASGR2 Antibody—艾普蒂

+ +

•  

   

     Black line: Control Antigen (100 ng);Purple line: Antigen (10ng); Blue line: Antigen (50 ng); Red line:Antigen (100 ng)    

  
  

•  

   

     Flow cytometric analysis of Hela cells using ASGR2 mouse mAb (green) and negative control (red).    

  
  

•  

   

     Immunohistochemical analysis of paraffin-embedded human liver cancer tissues using ASGR2 mouse mAb with DAB staining.    

  
  

•  

   

     Immunohistochemical analysis of paraffin-embedded human bladder cancer tissues using ASGR2 mouse mAb with DAB staining.    

  
  

The asialoglycoprotein receptor 2 (ASGR2) is a transmembrane protein belonging to the C-type lectin family, primarily expressed on hepatocytes. It forms heterodimers with ASGR1 to mediate the clearance of desialylated glycoproteins by recognizing terminal galactose or N-acetylgalactosamine residues. ASGR2 plays a critical role in maintaining serum glycoprotein homeostasis and has been implicated in liver physiology, including cholesterol metabolism and viral entry mechanisms (e.g., hepatitis B virus).

ASGR2 antibodies are tools developed to study the receptor's expression, function, and interaction partners. In research, they are used in applications such as immunohistochemistry, Western blotting, and flow cytometry to investigate ASGR2 localization and dynamics in liver diseases, including hepatocellular carcinoma and metabolic disorders. Therapeutically, ASGR2 has emerged as a potential target for liver-directed therapies. Antibody-based approaches, such as antibody-drug conjugates or bispecific antibodies, are being explored to deliver cytotoxic agents or modulate receptor activity in cancers and hypercholesterolemia.

Recent studies highlight ASGR2's involvement in tumor progression and immune evasion, driving interest in its diagnostic and prognostic value. However, challenges remain in optimizing antibody specificity and minimizing off-target effects due to structural similarities with other lectins. Ongoing research aims to leverage ASGR2 antibodies for precision medicine in hepatobiliary pathologies.